Tarsus prices USD 125 million PIPE at USD 56 per share
TARS•PIPE priced at $56 per share
- Tarsus Pharmaceuticals priced an oversubscribed $125 million PIPE, selling 2,098,519 common shares at $56 per share.
- The deal also includes pre-funded warrants for 133,625 shares at $56 each, with a $0.0001 exercise price.
- Closing is expected on Aug. 7, 2026, subject to customary conditions.
- Proceeds are earmarked for clinical development, commercial activities, and general corporate purposes.
- Barclays is lead placement agent; BofA Securities and William Blair are co-placement agents.
Related News
Select Water Solutions, Inc. <WTTR.N>: Raymond James cuts to outperform from strong buy; raises target price to $26 from $24
WTTR•
Charter upsizes debt exchange offers, raises new secured notes caps to USD 2 billion each
CHTR•
